Progress in the overall understanding of typhoid fever: implications for vaccine development.


Journal

Expert review of vaccines
ISSN: 1744-8395
Titre abrégé: Expert Rev Vaccines
Pays: England
ID NLM: 101155475

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 3 4 2020
medline: 18 3 2021
entrez: 3 4 2020
Statut: ppublish

Résumé

Typhoid fever continues to have a substantial impact on human health, especially in Asia and sub-Saharan Africa. Access to safe water, and adequate sanitation and hygiene remain the cornerstone of prevention, but these are not widely available in many impoverished settings. The emergence of antibiotic resistance affects typhoid treatment and adds urgency to typhoid control efforts. Vaccines provide opportunities to prevent and control typhoid fever in endemic settings. Literature search was performed looking for evidence concerning the global burden of typhoid and strategies for the prevention and treatment of typhoid fever. Cost of illness, available typhoid and paratyphoid vaccines and cost-effectiveness were also reviewed. The objective was to provide a critical overview of typhoid fever, in order to assess the current understanding and potential future directions for typhoid treatment and control. Our understanding of typhoid burden and methods of prevention has grown over recent years. However, typhoid fever still has a significant impact on health in low and middle-income countries. Introduction of typhoid conjugate vaccines to the immunization schedule is expected to make a major contribution to control of typhoid fever in endemic countries, although vaccination alone is unlikely to eliminate the disease.

Identifiants

pubmed: 32238006
doi: 10.1080/14760584.2020.1750375
doi:

Substances chimiques

Typhoid-Paratyphoid Vaccines 0
Vaccines, Conjugate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-382

Auteurs

Peter J O'Reilly (PJ)

Oxford Vaccine Group, Department of Pediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre , Oxford, UK.

Dikshya Pant (D)

Department of Paediatrics, Patan Academy of Health Sciences, Patan Hospital , Kathmandu, Nepal.

Mila Shakya (M)

Oxford University Clinical Research Unit, Patan Academy of Health Sciences , Kathmandu, Nepal.

Buddha Basnyat (B)

Oxford University Clinical Research Unit, Patan Academy of Health Sciences , Kathmandu, Nepal.

Andrew J Pollard (AJ)

Oxford Vaccine Group, Department of Pediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre , Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH